The evolution of non-surgical management in stage III non-small cell lung cancer
{{output}}
The management of unresectable stage III non-small cell lung cancer (NSCLC) continues to evolve with the integration of immunotherapy and targeted agents into treatment paradigms. The PACIFIC trial established consolidation durvalumab following concurrent chem... ...
